OncLive TV

Alexey V. Danilov, MD, PhD, discusses the rationale to combine entospletinib with obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Daniel Catenacci, MD, discusses recent updates in gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

Omar Castaneda Puglianini, MD, hematologist and medical oncologist, Moffitt Cancer Center, discusses next steps with CAR T-cell therapy in penta-refractory multiple myeloma.

Bob T. Li, MD, PhD, MPH, discusses the limitations of the phase 3 IMpower010 trial in resected stage IB to IIIA non–small cell lung cancer.

Melissa L. Johnson, MD, discusses the promise of DS-7300 in small cell lung cancer and other advanced solid tumors.

Alexander I. Spira, MD, PhD, FACP, discusses the results of the phase 1 TROPION-PanTumor01 trial in non–small cell lung cancer.

Srdan Verstovsek, MD, PhD, discusses the benefit of drug combinations to improve anemia in patients with myelofibrosis.

Brandon Blue, MD, discusses treatment considerations for patients with relapsed/refractory multiple myeloma.

Raajit K. Rampal, MD, PhD, discusses the importance of risk stratification in myelofibrosis.

Anish Thomas, MBBS, MD, medical oncologist, Lasker Clinical Research Scholar, Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, discusses the rationale for the phase 2 DDRiver SCLC 250 trial in relapsed, platinum-resistant small cell lung cancer.

Erika P. Hamilton, MD, discusses the utility of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer.

Jason Brayer, MD, PhD, discusses bispecific antibodies and T-cell engagers as alternative options to CAR T-cell therapy in patients with multiple myeloma. 

Susan Tsai, MD, MHS, discusses ongoing research efforts being made in the realm of pancreatic cancer. 

Doris Hansen, MD, discusses the promise of ALLO-715 in relapsed/refractory multiple myeloma. Scroll to 0:07 in the video for Dr. Hansen's topline points on the agent.

Tiffany S. Lai, MD, discusses the role of maintenance therapy and secondary cytoreduction in ovarian cancer.

Puja S. Venkat, MD, discusses treatment considerations for patients with ovarian cancer.

Irene Ghobrial, MD, discusses the key objectives of the PROMISE study in multiple myeloma.

Pavlos Msaouel, MD, PhD, discusses how exercise can influence risk for patients with sickle cell trait to develop renal medullary carcinoma.

Eric Jonasch, MD, discusses recent pivotal developments in treating patients with renal cell carcinoma.

Yousef Zakharia, MD, discusses the role of seleno-L-methionine in previously treated advanced clear cell renal cell carcinoma.

Bradley McGregor, MD, discusses ongoing trials in patients with non-clear cell renal cell carcinoma (RCC).

Rana R. McKay, MD, discusses the outcomes of landmark clinical trials in frontline renal cell carcinoma.

Tian Zhang, MD, discusses the ongoing phase 3 PDIGREE trial, evaluating the combination ipilimumab plus nivolumab, followed by nivolumab with or without cabozantinib, in patients with advanced renal cell cancer.

Kevin Zarrabi, MD, discusses an analysis of real-world outcomes with axitinib plus pembrolizumab vs ipilimumab plus nivolumab in patients with metastatic clear cell renal cell carcinoma.

Daniel H. Ahn, DO, discusses the increased understanding of cholangiocarcinoma.

Muhamed Baljevic, MD, discusses the current limitations of CAR T-cell therapy in multiple myeloma.

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses mitigating belantamab mafodotin-blmf–related keratopathy in relapsed/refractory multiple myeloma.

Mario Spaggiari, MD, discusses surgical interventions in colorectal cancer with liver metastases.

Douglas W. Sborov, MD, MS, discusses supportive care approaches for selinexor-associated toxicities in multiple myeloma.

Angeles A. Secord, MD, discusses the individual therapeutic preferences and treatment considerations for patients with platinum-sensitive ovarian cancer.